Abstract: Objective: To observe the efficacy and tolerance of PD-1 antibody combined with anti-vascularized targeted therapy in advanced recurrent metastatic head and neck tumors. Methods: The clinical data of 4 patients with advanced recurrence and metastatic head and neck tumors treated with PD-1 monoclonal antibody combined with anti-vascular targeted therapy were retrospectively analyzed. RECIST 1.1 was used to evaluate the efficacy of 4 patients and observe their tolerance to treatment. Results: In the 4 patients treated with PD-1 monoclonal antibody combined with anti-vessel targeted therapy, 1 patient achieved CR, 1 patient achieved PR, 1 patient showed focal shrinkage and symptom relief despite SD, and 1 patient showed PD. No bleeding occurred during the medication, and the overall tolerance of the patients to the treatment was good, with no significant grade 3-4 adverse reactions. Conclusion: PD-1 antibody combined with anti-vascular targeted therapy is a new choice for the treatment of head and neck tumors with advanced recurrence and metastasis, and it is well tolerated.

Key words: anti-PD-1 antibody, Apatinib, advanced recurrence and metastasis, head and neck tumor